logo-loader

SkinBioTherapeutics safety data out on first human studies

Published: 09:50 12 Nov 2018 GMT

SkinBioTherapeutics' (LON:SBTX) Dr. Catherine O'Neill tells Proactive Investors London about an important milestone for the company's skin irritancy product, as the results from their first human studies are announced. O'Neill says the team is 'very pleased' with the data which allows them now to scale up their technology to a cream and take it to manufacturing.

These initial results are effectively a precursor to the main element of the study involving 120 volunteers with dry skin. This kicks off later in November and will assess the longer-term moisturisation potential of the technology.

Accesso's landmark deal with SEVEN marks strategic growth in the Saudi Market

Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) chief executive Steve Brown joins Proactive's Stephen Gunnion with details of a significant partnership with Saudi Entertainment Ventures (SEVEN). Brown noted the collaboration highlights accesso's strategy to grow its global footprint,...

10 minutes ago